Loading patent…
AssigneeRoche Diagnostics Operations, Inc.
InventorsHarald SOBEK, Michael GREIF, Marco THOMANN, Sebastian MALIK
Estimating the term…
The present disclosure is directed to the properties of certain glycosyltransferase variants having N-terminal truncation deletions or internal deletions. Any of the mutants disclosed in here exhibit α-2,6-sialyltransferase enzymatic activity in the presence of CMP-activated sialic acid as co-substrate, and in the presence of a suitable acceptor site. A fundamental finding documented in the present disclosure is that such enzyme are not only capable of catalyzing transfer of a sialidyl moiety but they are also capable of catalyzing hydrolytic cleavage of terminally bound sialic acid from a glycan.
1-10. (canceled)
A method of producing in vitro a sialylated target molecule, the method comprising the steps of
Dependencies are inferred from the claim text.